ROCKVILLE, Md.--(BUSINESS WIRE)--Celera Genomics Group (NYSE:CRA), an Applera Corporation business, today reported a net loss of $7.1 million, or $0.09 per share, for the first quarter of fiscal 2007 ended September 30, 2006, compared to a net loss of $16.7 million, or $0.23 per share, for the first quarter of fiscal 2006. Included in the results for the first quarter of fiscal 2007 was a pre-tax charge of $3.5 million for Celera’s estimated share of the damage award in continuing litigation between Abbott Laboratories, Celera’s alliance partner, and Innogenetics N.V., Ghent, Belgium. The first quarter of fiscal 2006 included a pre-tax gain of $4.5 million from the sale of an investment. All per share amounts refer to Applera Corporation-Celera Genomics Group Common Stock.
